Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry

Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : Melinda L. Telli Ellen T. Chang Allison W. Kurian Theresa H. M. Keegan Laura A. McClure Daphne Lichtensztajn James M. Ford Scarlett L. G
  • چاپ و سال / کشور: 2010

Description

The distribution of breast cancer molecular subtypes has been shown to vary by race/ethnicity, highlighting the importance of host factors in breast tumor biology. We undertook the current analysis to determine population-based distributions of breast cancer subtypes among six ethnic Asian groups in California. We defined immunohistochemical (IHC) surrogates for each breast cancer subtype among Chinese, Japanese, Filipina, Korean, Vietnamese, and South Asian patients diagnosed with incident, primary, invasive breast cancer between 2002 and 2007 in the California Cancer Registry as: hormone receptor-positive (HR?)/HER2- [estrogen receptor-positive (ER?) and/or progesterone receptor-positive (PR?), human epidermal growth factor receptor 2-negative (HER2-)], triple-negative (ER-, PR-, and HER2-), and HER2-positive (ER±, PR±, and HER2?). We calculated frequencies of breast cancer subtypes among Asian ethnic groups and evaluated their associations with clinical and demographic factors. Complete IHC data were available for 8,140 Asian women. Compared to non-Hispanic White women, Korean [odds ratio (OR) = 1.8, 95% confidence interval (CI) = 1.5–2.2], Filipina (OR = 1.3, 95% CI = 1.2–1.5), Vietnamese (OR = 1.3, 95% CI = 1.1–1.6), and Chinese (OR = 1.1, 95% CI = 1.0–1.3) women had a significantly increased risk of being diagnosed with HER2- positive breast cancer subtypes after adjusting for age, stage, grade, socioeconomic status, histology, diagnosis year, nativity, and hospital ownership status. We report a significant ethnic disparity in HER2-positive breast cancer in a large population-based cohort enriched for Asian- Americans. Given the poor prognosis and high treatment costs of HER2-positive breast cancer, our results have implications for healthcare resource utilization, cancer biology, and clinical care.
Breast Cancer Res Treat (2011) 127:471–478 DOI 10.1007/s10549-010-1173-8 Received: 16 May 2010 / Accepted: 9 September 2010 / Published online: 19 October 2010  Springer Science+Business Media, LLC. 2010
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری